Peptides are too specific in their mechanism to interact with prescription medications. Unlike small molecules that hit multiple targets, peptides bind narrowly and don't cause drug interactions.

The "peptides don't interact with prescription drugs" framing recurs in biohacker forums, vendor copy, and "peptides are safer than pharmaceuticals" comparisons. It contains a real mechanistic observation and an unjustified inferential leap, and the gap between the two is where patient-safety risk actually lives.

Where the steelman is real

Many peptides do bind their primary receptor with selectivity that small molecules of comparable potency rarely achieve. Ipamorelin is the cleanest example in the corpus: at relevant doses it agonizes GHSR-1a without the cortisol and prolactin spillover that characterized first-generation GH secretagogues like GHRP-2 and hexarelin (Raun et al., Eur J Endocrinol 1998, 139:552–561). SS-31 binds cardiolipin selectively on the inner mitochondrial membrane and does not interact significantly with other inner-membrane phospholipids (Birk et al. 2013). The mechanism-level selectivity claim is not nothing — for several molecules on this site, it is a genuine pharmacological feature distinguishing them from broad-acting small-molecule analogs.

Why receptor specificity does not equal interaction absence

Drug-drug interactions do not require shared receptor binding. They arise through any pathway by which one drug modifies another's exposure, clearance, or downstream physiological substrate. The relevant axes in peptide pharmacology: shared organ systems (hepatic metabolism, renal clearance, biliary excretion as finite shared resources); downstream physiological cascades (GLP-1 receptor agonism slows gastric emptying as a downstream consequence of receptor activation, not a receptor-level effect, and that change modifies the absorption rate of every oral drug taken concurrently); endocrine-axis cross-talk (GH-axis stimulation modulates insulin signaling, HPG-axis modulation interacts with every sex-steroid-dependent pharmacology, melanocortin agonism affects vascular tone); cardiovascular and hemostatic effects (acute blood-pressure changes interact with antihypertensive titration, pro-angiogenic signaling raises theoretical questions for anticoagulants and antiplatelets); and immunological modulation (compounds that adjust T-cell or innate-immune signaling overlap predictably with immunosuppressive pharmacology). None of these mechanisms require the peptide and the interacting drug to share a receptor target. The "specific binding" claim addresses one of the many surfaces along which interaction can occur.

Documented interactions in FDA-approved peptide labels

The package inserts for the peptides on this site that have reached FDA approval each include drug-interaction sections — empirical evidence that regulators reviewing peptide pharmacology did not accept the no-interaction framing.

The Wegovy / Ozempic / Rybelsus prescribing information for semaglutide documents that gastric-emptying delay can alter absorption of concomitant oral medications, with specific monitoring guidance for warfarin (delayed Tmax) and a 33% increase in levothyroxine exposure observed when oral semaglutide and levothyroxine are co-administered (Novo Nordisk, Rybelsus prescribing information). The Mounjaro and Zepbound label for tirzepatide goes further: a single 5 mg dose reduced ethinyl estradiol Cmax by 59% and norgestimate Cmax by 66% in co-administered oral contraceptive pharmacokinetic studies, with the label recommending barrier or non-oral contraception for 4 weeks after initiation and after each dose escalation (Eli Lilly, Mounjaro prescribing information). The Saxenda label for liraglutide carries equivalent gastric-emptying-driven interaction warnings.

The Egrifta SV label for tesamorelin explicitly addresses interaction with insulin and oral hypoglycemic agents: growth-hormone-releasing factors decrease insulin sensitivity, and patients on insulin, sulfonylureas, or other glucose-lowering pharmacology may require dose adjustment and intensified glycemic monitoring during initiation (Theratechnologies, Egrifta SV prescribing information). The Vyleesi label for PT-141 documents two distinct interaction patterns: slowed gastric emptying may reduce absorption of concomitant oral drugs (with explicit guidance to avoid use with oral medications dependent on threshold concentrations, such as antibiotics), and clinically significant reduction in oral naltrexone systemic exposure with the recommendation to avoid co-administration with orally-administered naltrexone-containing products intended to treat alcohol or opioid addiction (Palatin Technologies, Vyleesi prescribing information). The September 2025 Forzinity label for elamipretide (the FDA-approved formulation of SS-31 for Barth syndrome) addresses dose modification in renal impairment among other label considerations (Stealth BioTherapeutics, Forzinity prescribing information).

These are not theoretical concerns. They are the empirical-pharmacology entries in regulatory dossiers reviewed by the same agency that approved each molecule.

Class-level interaction patterns

Beyond the individual-molecule labels, several peptide classes carry interaction profiles that follow predictably from class mechanism rather than from any single molecule's pharmacokinetics.

GH-axis modulators — ipamorelin, CJC-1295, tesamorelin, sermorelin, hexarelin, GHRP-2, MK-677 — share a class interaction with diabetes pharmacology through the GH-axis effect on insulin sensitivity. The Nass 2008 MK-677 trial documented a 0.3 mmol/L fasting-glucose elevation at one year (Nass et al. 2008); the same mechanism predicts that patients on metformin, sulfonylureas, SGLT2 inhibitors, or insulin may need dose re-evaluation when GH-axis peptides are added. This is a class effect documented in the Egrifta label and consistent across the GHRH/GHRP literature, not a quirk of any single molecule. The GH axis dossier covers the broader pharmacology.

HPG-axis modulators — hCG, gonadorelin, kisspeptin — interact with the full sex-steroid pharmacology that biohacker and clinician practice already layers around them: testosterone replacement, SERMs (clomiphene, tamoxifen), aromatase inhibitors (anastrozole, exemestane). Stacking is sometimes intentional, but the pharmacology is interaction-rich by design, not interaction-free.

Melanocortin agonists — PT-141, melanotan II — produce transient blood-pressure elevation peaking within 4 hours and returning toward baseline by 8–10 hours. In patients on antihypertensive therapy, this is a documented mechanism-level concern, and the Vyleesi label contraindicates use in uncontrolled hypertension. Co-administration with vasoactive medication sits in the safety frame the trials studied around — not outside it.

Mitochondrial peptides — SS-31, MOTS-c — and the cosmetic copper peptide GHK-Cu sit in less-characterized space. Mitochondrial-pathway modulation suggests theoretical overlap with metformin, biguanides, and statins (via CoQ10 effects), though controlled drug-interaction data is absent. Copper-budget considerations for GHK-Cu interact predictably with zinc supplementation, copper IUDs, and Wilson's disease pharmacology.

The uncharacterized gray-market space

For the peptides on this site without FDA approval, the drug-interaction literature is thin rather than zero. BPC-157, TB-500, and KPV have no published controlled drug-interaction studies; the pro-angiogenic mechanism documented in Hsieh et al. 2016 (VEGFR2-Akt-eNOS activation) raises theoretical questions about co-administration with anticoagulants and antiplatelet therapy that have not been resolved in controlled human work. The Russian cognitive peptides — selank, semax, cerebrolysin — have substantial Russian-language clinical literature on combined use with neuropsychiatric pharmacology, but the English-language Western drug-interaction record is sparse, and treating absence-of-Western-publication as absence-of-interaction misreads the corpus.

Why "narrow binding" misframes even the receptor pharmacology

The receptor-selectivity claim is also weaker than the framing suggests for several peptides on this site. Melanotan II is a pan-melanocortin agonist active at MC1, MC3, MC4, and MC5 receptors — the opposite of selective. Hexarelin binds both GHSR-1a (Kd in the nanomolar range) and the CD36 scavenger receptor in cardiomyocytes, with the cardiac CD36 binding documented as a parallel mechanism rather than off-target noise (Bodart et al. 2002). Kisspeptin acts upstream of GnRH and propagates through every downstream pituitary hormone in the HPG axis. Tirzepatide and retatrutide are intentional polypharmacology — dual and triple incretin-receptor agonism is the design specification, not a limitation. The "binds narrowly" frame is a stylized version of the receptor pharmacology that does not survive close reading.

What the page recommends, in plain terms

Before starting any peptide, the medication list — prescription, over-the-counter, supplement — should be documented. For FDA-approved peptides, the package insert's drug-interaction section is the most rigorous available source and should be read in full. For research peptides, the trial literature should be searched explicitly for interaction data; absence-of-finding from this search is itself information. The prescribing clinician (or, for research-only use, the user's existing prescriber for any concurrent medication) should be asked explicitly whether the peptide interacts with what they have already prescribed — even if the user is not asking that clinician to prescribe the peptide. The reasonable default is to assume that interaction data for gray-market peptides is thin rather than absent, and to weight clinical caution accordingly. The peptide pharmacokinetics matrix and the peptide storage and stability reference provide the broader handling context; the stacking critic covers the adjacent question of peptide-peptide pharmacology in stacks.

What this page does not claim

The receptor-level selectivity of many peptides remains a genuine pharmacological feature, and the gastrointestinal-tolerability advantage of receptor-selective agonists over their broader-acting predecessors is real. The narrow claim being rejected is that this receptor-level selectivity translates upward into a category-wide absence of clinical drug interactions. The FDA-approved peptide labels, the class-level endocrine pharmacology, and the unstudied interaction space for the gray-market peptides each contradict that framing along a different axis. The honest version is that peptide drug interactions are class-specific, mechanism-specific, and often labeled — and that "peptides don't interact" is the kind of category-flattening claim the actual pharmacology will not support.